Similarly, in the clinical testing of MK-2075, another small-molecule selective Nav1.7 inhibitor, orthostatic hypotension linked to Nav1.7-dependent cardiac autonomic dysfunction was observed in patients administered with either 30 mg by intravenous infusion over 8 h or 8 mg over 2 h [186]. This evidence concerns the gene SCN9A and orthostatic hypotension.